Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02680751 2014-09-23
- 1 -
SPECIFICATION
USE OF DIOXABICYCLO [3 .3 .0]0CTANE DERIVATIVES AS ANTI-FATIGUE AGENTS
TECHNICAL FIELD
100011 The present invention relates to anti-fatigue agents containing as the
active
ingredient dioxabicyclo[3.3.0]octane derivatives such as sesamin that are
represented by the
following general formula (I)
[0002] [Chemical Formula 1]
___53y0Rz 0
IV 0
0 (0)U ( )
(Po) 40 OR
OR
(OR') .a
(where RI, R2, R3, R4, R5 and R6 each independently represent a hydrogen atom,
an alkyl
group having 1-3 carbon atoms, or RI and R2 and/or R4 and R5, when taken
together,
represent a methylene group or an ethylene group, and n, m, and / represent 0
or 1), as well as
pharmaceutical compositions (including physiologically functional foods)
having an
anti-fatigue action.
BACKGROUND ART
[0003] Fatigue is a disease that generally involves feelings of weariness
(tiredness) and
malaise (lassitude) as main symptoms but which is also accompanied by varied
other
symptoms including sleep disorder and lowered motivation. Feelings of
weariness
(tiredness) and malaise (lassitude) are one of the important alarm signals for
a certain
abnormality in the body and even healthy persons may perceive fatigue if they
take heavy
exercise, work for a prolonged period, or when they are given extreme stress.
Such
physiological fatigue is usually restored to the initial normal state by rest
and will not last for
long. According to "A Survey on Public Perception of Health" conducted by the
Prime
CA 02680751 2009-09-14
- 2 -
Minister's Office in 1985, about 60% plus of the people surveyed complained of
fatigue but
70% of those who complained of fatigue said that "their fatigue was restored
by a night's
sleep." However, modern people are in many cases forced to work for a
prolonged period
of time or given extreme stress and yet hey have difficulty taking enough
rest, so they
frequency find it difficult to recover from feelings of weariness (tiredness)
or malaise
(lassitude). According to the epidemiological research conducted by the
fatigue survey
study group of the Health and Welfare Ministry in 1999, the proportion of the
people who
perceived fatigue remained unchanged and accounted for about 60% but then as
much as
60% of those people were reported to have felt tired for more than six months.
Thus, in the
past 14 years, more people have become afflicted with chronic fatigue,
indicating a change in
the nature of fatigue (Non-Patent Document 1).
[0004] A very recent topic related to fatigue is chronic fatigue syndrome
(CFS) which is
considered to be one of intractable disorders. In Europe and the U.S., the
first onset of this
disorder was reported almost 20 years ago but here in Japan it was not until
about 1991 that a
fact-finding survey was launched by a dedicated study group of the Health and
Welfare
Ministry. General symptoms of chronic fatigue syndrome include systemic
feelings of
weariness (tiredness) and malaise (lassitude), slight fever, lymph node
dilation, muscle pain,
joint pain, and psychoneurotic symptoms, all being so prolonged as to
potentially interfere
with the daily life of the affected individual. Another topic of the day is
"death by
overwork" which presents itself as a big social problem. Death by overwork is
defined as a
sudden death due to prolonged overloaded work. The problem of death by
overwork is
recognized to be of extreme importance from medical, economic and social
viewpoints.
[0005] Under these circumstances, so-called "anti-fatigue substances" have
been proposed,
such as those which are capable of relieving the fatigue that is experienced
after taking heavy
exercise, working for a prolonged time, or being given excessive stress, and
those which are
capable of recovery from fatigue to the normal state. For example, certain
kinds of amino
acid compositions (Patent Document 1), L-carnitine and histidine-related
dipeptides (Patent
Document 2), hawthorn extracts (Patent Document 3) and the like have been
reported to have
CA 02680751 2015-09-01
- 3 -
a body strength increasing action. In addition; nutrition support compositions
containing
ascorbic acid have been shown to be useful for the purpose of furnishing
nutrition when one
has lost their bodily strength due, for example, to exercise or at such times
that one is tired
(Patent Document 4).
10006] The above-mentioned ascorbic acid is also known to be effective in
symptomatic
therapy for treating chronic fatigue syndrome (Non-Patent Document 2), and it
has also been
suggested that acetyl-L-c.arnitine is effective in the treatment of chronic
fatigue syndrome
(Patent Document 5).
[0007] As regards sesamin and/or episesamin, the Assignee of the subject
application has
shown that they have an autonomic nerve regulating action (Patent Document 6).
They are
also shown to have an action for alleviating the symptoms of withdrawal from
alcohol or
tobacco intoxication (Patent Document 7). However, none of these documents
suggest or
disclose the anti-fatigue action.
[Patent Document 1] Official Gazette of JP 9-124473 A
[Patent Document 2] Official Gazette of JP 2001-046021 A
[Patent Document 3] Official Gazette of JP 8-47381 A
[Patent Document 4] Official Gazette of JP 6-327435 A
[Patent Document 5] Official Gazette of JP 8-26987 A
[Patent Document 6] International Publication WO 2004-105749
[Patent Document 7] Official Gazette of USP 442769"
[Non-patent document 1] M. Inoue et al. "Hirou no kagaku" (Science on Fatigue)
published
by Kodansha on May 20, 2001, p. 222-228
[Non-Patent Document 2] In Vivo (1996) Nov-Dec;10(6):585-96
DISCLOSURE OF THE INVENTION
PROBLEM TO BE SOLVED BY THE INVENTION
[0008] An object of the present invention is to provide compositions, in
particular,
pharmaceutical compositions that are safe to humans and animals alike and
which therefore
allow for continued ingestion while proving effective in preventing and/or
treating fatigue.
MEANS FOR SOLVING THE PROBLEM
CA 02680751 2009-09-14
- 4 -
[0009] The present inventors conducted intensive studies with a view to
solving the
above-mentioned problem; as a result, they found that
dioxabicyclo[3.3.0]octane derivatives
such as sesamin which is an ingredient in sesame have the activity of
promoting an
improvement of stamina, an increase in body strength, a relief of fatigue, and
recovery from
fatigue; the present invention has been accomplished on the basis of this
finding.
[0010] Thus, the present invention relates to the following:
1. An anti-fatigue agent containing as the active ingredient a
dioxabicyclo[3.3.0]octane
derivative such as sesamin that is represented by the following general
formula (I)
[0011] [Chemical Formula 2]
R,.....4-7-y-OR2 0
0
0 (0) t, ( )
(R30) if 411i OR
0 R 5
(OP)
(where RI, R2, R3, -4,
K R5 and R6 each independently represent a hydrogen atom, an alkyl
group having 1-3 carbon atoms, or R1 and R2 and/or R4 and R5, when taken
together,
represent a methylene group or an ethylene group, and n, m, and / represent 0
or 1).
2. The anti-fatigue agent according to 1 above, wherein the
dioxabicyclo[3.3.0]octane
derivative is sesamin.
3. A pharmaceutical composition containing the anti-fatigue agent according to
1 or 2 above,
for treating or preventing a disorder that involves fatigue.
4. The pharmaceutical composition according to 3 above, wherein the disorder
that involves
fatigue is chronic fatigue syndrome.
5. Use of the dioxabicyclo[3.3.0]octane derivative according to 1 above, for
recovery from
fatigue or prevention of fatigue.
6. The use according to 5 above, wherein the dioxabicyclo[3.3.0]octane
derivative is sesamin.
CA 02680751 2009-09-14
-5-
7. The use according to 5 or 6 above, for treating or preventing a disorder
that involves
fatigue.
8. The use according to 7 above, wherein the disorder that involves fatigue is
chronic fatigue
syndrome.
ADVANTAGES OF THE INVENTION
[0012] The anti-fatigue agents of the present invention have an outstanding
action for
promoting an improvement of stamina, an increase in body strength, a relief of
fatigue, and
recovery from fatigue and, what is more, they can be safely administered to
humans and
animals alike and hence allow for continued ingestion. Therefore, the anti-
fatigue agents of
the present invention are widely applicable as pharmaceutical compositions
including
physiologically functional foods.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a graph showing how the administration of sesamin was
effective for
controlling the shortening of the swimming time (for relieving fatigue) in a
forced swimming
test under load.
FIG. 2 is a graph showing by motor activity the degree by which rats recovered
from
fatigue in a forced exercise test when they were administered sesamin.
FIG. 3 is a graph showing by motor activity the degree by which rats were
prevented
from becoming tired in a forced exercise test when they were administered
sesamin.
FIG. 4 is a graph showing how the administration of sesamin was effective for
controlling the elevation of serum level of ketone bodies in the measurement
of
fatigue-causing substances in the blood.
BEST MODE FOR CARRYING OUT THE INVENTION
[0014] (dioxabicyclo[3.3.0]octane derivatives)
Examples of the dioxabicyclo[3.3.0]octane derivatives that may be used in the
present invention include sesamin, sesaminol, episesamin, episesaminol,
sesamolin,
methylenedioxypheny1)-6-(3-methox y-4-hydrox ypheny1)-3,7-
dioxabicyclo[3.3.0]octane, 2,6-
bis-(3-methoxy-4-hydroxypheny1)-3,7-dioxabicyclo[3.3.0]octane, 2-(3,4-
CA 02680751 2009-09-14
- 6 -
methylenedioxypheny1)-6-(3-methoxy-4-hydroxyphenoxy)-3,7-
dioxabicyclo[3.3.0]octane, 2-
(3-methoxy-4-hydroxypheny1)-6-(3,4-dihydroxypheny1)-3,7-
dioxabicyclo[3.3.0]octane, 2,6-
bis(3,4-dihydroxypheny1)-3,7-dioxabicyclo[3.3.0]octane, 2-(3,4-
methylenedioxypheny1)-6-
(3,4-dihydroxypheny1)-3,7-dioxabicyclo[3.3.0]octane, etc. These stereoisomers
or
racemates may be used either alone or in admixture, and among others, sesamin
may be used
with advantage.
[0015] Sesamin as used herein shall mean sesamin and/or episesamin. In
addition, the
metabolites of sesamin that are described in the official gazette of JP 2001-
139579 A may, as
long as they exhibit the effects of the present invention, be
classified as the dioxabicyclo[3.3.0]octane derivatives of the present
invention and can be
used in the present invention. Those compounds which are to be used in the
present
invention and extracts that contain those compounds as main ingredients can be
obtained by
known methods such as the one described in Japanese Patent No. 3075358.
[0016] The compounds to be used in the present invention are either compounds
that have
been discovered in existing foods or their analogous compounds, so they
obviously have
another advantage of outstanding safety. This is demonstrated by the fact that
7-week old
ICR male mice were continuously administered 2.14 g/day/kg of sesamin for two
weeks (by
oral route), with no abnormal symptoms being recognized.
(Anti-fatigue action and agent)
Ingesting the above-mentioned sesamin or other dioxabicyclo[3.3.0]octane
derivatives helps provide a marked anti-fatigue action. Fatigue as appears
here is a
temporary lowering of physical or mental performance that results from
continued
application of a physical or mental stress and lowered performance means a
drop in the
quality or quantity of a physical or mental working capacity. It should also
be noted that the
term "fatigue" as used herein covers chronic fatigue syndrome and death by
overwork.
[0017] The "anti-fatigue action" as used herein, namely, the effect of the
"anti-fatigue
agent" refers to its action for attenuating the above-defined fatigue or
achieving recovery
from it and includes the following effects: prolonging the duration for which
a moving or
CA 02680751 2009-09-14
- 7 -
acting site (including the brain) keeps functioning, and controlling the
increase in
fatigue-causing substances given the same amount of motion or action
(improvement of
stamina and increase of body strength); or ameliorating such a condition that
the brain or
nerves have come to perceive fatigue although a moving or acting site is yet
to get tired, and
promoting the recovery of the moving or acting site from the tired state to
the normal state.
[0018] Chronic fatigue syndrome which is to be treated with the anti-fatigue
agent of the
present invention means general symptoms such as systemic feelings of
weariness (tiredness)
and malaise (lassitude), slight fever, lymph node dilation, muscle pain, joint
pain, and
psychoneurotic symptoms, all being so prolonged as to potentially interfere
with the daily life
of the affected individual. The anti-fatigue agent of the present invention is
capable of
treating chronic fatigue syndrome; in other words, it can palliate the various
symptoms of
chronic fatigue syndrome such that the affected individual is brought to the
normal condition.
Death by overwork which is also to be treated with the anti-fatigue agent of
the present
invention means such a condition of individuals who are under extreme fatigue
and unable to
keep physical vigor that they are no longer capable of fully perceiving
fatigue, with the result
that cardiovascular disease or cardiac disease manifests itself, causing the
individuals to
become permanently unable to work or bringing them to death. The anti-fatigue
agent of
the present invention is capable of treating chronic fatigue syndrome, whereby
it can prevent
death from overwork.
[0019] The effectiveness of the "anti-fatigue agent" of the present invention
can be verified
by the following tests.
[0020] The first thing to do is measure the swimming time in a water immersion
sleep
disturbed test. Mice that have been kept in an environment such as water
immersion where
they are unable to have a good sleep or take a rest position so they cannot
have a physical or
mental rest are forced to swim under a weight load and the time it takes for
them to have their
nose sunk in the water for a period of ten seconds or longer is measured to
confirm the degree
of their fatigue. Since this is an animal model for physical or mental
fatigue, an extension
of the swimming time as achieved by administering it with the test substance
means the
CA 02680751 2009-09-14
- 8 -
verification of resistance to fatigue, as exemplified by relief of physical
and/or mental
fatigue, maintenance of physical vigor in the tired model (increase in body
strength), or
improvement of stamina.
[0021] The second thing to do is measure the motor activity in a forced
exercise test. Rats
administered with the test substance are forced to have exercise on a
treadmill and, thereafter,
the motor activity of the animal in the dark period is measured. Since this is
an animal
model for fatigue from exercise (physical fatigue), an increase in the motor
activity as
achieved by administering it with the test substance means the verification of
resistance to
fatigue.
[0022] The third thing to do is measure the amount of fatigue-causing
substances in the
blood. This involves administering the test substance to check to see if it
has an action for
controlling an increase in the blood concentration of fatigue-causing
substances under a
physical or mental stress. Although no substances have been identified to be
causative of
fatigue, one class of candidates may be ketone bodies (collectively referring
to acetoacetate,
3-hydroxybutyrate, and acetone). Ketone bodies are known to be metabolites
that are
produced when free fatty acids immobilized from the fat tissue on account of
lowered
glucose availability undergo 13-oxidation. If the production of ketone bodies
is enhanced
beyond their utilization in the extrahepatic tissues, ketone bodies accumulate
in the blood,
leading to ketosis. Actoacetate and 3-hydroxybutyrate are moderately strong
acids, so if
ketone bodies accumulate in amounts exceeding the buffering action of the
living body, the
blood becomes acidic, causing a condition known as acidosis which, in turn,
produces a
feeling of weariness (Takanori Yamamoto, Igaku no ayumi (Progress in
Medicine), Vol. 204,
No. 5:325-329, 2003).
[0023] Sesamin used as a dioxabicyclo[3.3.0]octane derivative has been
verified to have a
fatigue-resisting effect in each of the above-described tests for anti-fatigue
action, namely, in
the water immersion sleep disturbed test, forced exercise test, and the
measurement of the
amount of fatigue-causing substances. This means sesamin is useful not only as
an
anti-fatigue agent but also in preventing or treating chronic fatigue
syndrome, and in
CA 02680751 2009-09-14
- 9 -
preventing death from overwork. Since sesamin also controls an increase in
fatigue-causing
substances in the blood (ketone bodies), it may well be said that sesamin is
also useful as an
agent for ameliorating ketosis. Alanine, aspartic acid, and glutamine have
been reported to
be effective in reducing blood ketone levels in the living body (Romano
Nosadini, Biochem.
J., 190, 323-332, 1980; Eugenio Cersosimo, Am. J. Physiol., 250, E248-E252,
1986);
however, the effect of these amino acids for lowering ketone bodies is only
transient if they
are administered in a single dose and because of this short duration of their
efficacy, single
doses of these amino acids have to be administered frequently in order to
ameliorate ketosis.
In contrast, a ketosis ameliorating agent containing the
dioxabicyclo[3.3.0]octane derivative
such as sesamin of the present invention was shown to have an action for
reducing the levels
of ketone bodies when it was ingested for two consecutive days on a single-
dose-a-day basis
(see Example 4) and this ease of ingestion may also explain the superiority of
this ketosis
ameliorating agent.
[0024] As described above, the anti-fatigue agent of the present invention has
such an effect
that if one ingests it, he or she will not get tired easily and, if tired, may
soon recover from
the fatigue. In other words, if one perceives physical fatigue as a result of
taking a muscular
exercise such as sport or if one perceives mental fatigue as a result of a
continued work such
as a calculating operation, he or she may of course ingest the anti-fatigue
agent of the present
invention with a view to recovering from the fatigue; if desired, one may
ingest the
anti-fatigue agent of the present invention and then start working or doing
sport, without
perceiving much fatigue (the fatigue preventing effect). Ingesting it before
one does sport
or while one is doing sport, his or her stamina is likely to be improved. What
is more, if it is
ingested on a regular basis, not only mental fatigue but also some disorder
that accompanies
it can be prevented.
[0025] The anti-fatigue agent of the present invention can be used as a
pharmaceutical drug
or as food (i.e., one that may be administered perorally, as exemplified by
physiologically
functional foods, health supplements, foods with nutrient function claims,
foods for special
uses, and foods for specified health use). The anti-fatigue agent of the
present invention
CA 02680751 2009-09-14
- 10 -
may be used in such a way that the type of the active ingredient, the use for
which the agent
is indicated, its efficacy such as improved stamina or anti-fatigue effect,
and/or the method of
ingestion is identified on the package, container, or manual.
[0026] If the anti-fatigue agent of the present invention is to be used as a
pharmaceutical
drug, the dioxabicyclo[3.3.0]octane derivatives may be used either alone or
together with a
pharmacologically acceptable carrier, diluent, excipient or the like, for oral
administration in
the form of a liquid, tablet, granule, powder, capsule, dry syrup, pill or the
like, or for
parenteral administration in the form of an injection or the like. The dose
and dosage form
of the anti-fatigue agent may be chosen as appropriate for the subject to be
treated, his or her
pathological state, the severity of its progress, and other conditions; if
sesamin is chosen as
the dioxabicyclo[3.3.0]octane derivative and is to be administered perorally
with a view to
obtaining the anti-fatigue action in a human (adult) as the subject, then it
may generally be
administered continuously at a frequency of once or twice a day to give a
daily dose of about
1-200 mg, preferably about 5-100 mg. The present inventors made an
investigation using
mice or rats as tired animal models and confirmed that when it was desired to
relieve mental
or physical fatigue by preliminary administration of sesamin, the intended
anti-fatigue action
could be obtained by administering sesamin in an amount of about 10-100 mg/kg,
preferably
about 10-80 mg/kg, more preferably about 12.5-80 mg/kg, and even more
preferably about
50-80 mg/kg. The present inventors also confirmed that when it was desired to
promote
recovery from existing physical fatigue by administering sesamin, the intended
anti-fatigue
action could be obtained by administering sesamin in an amount of at least 100
mg/kg,
preferably at least 150 mg/kg, more preferably at least 180 mg/kg.
[0027] In the case of parenteral administration, the anti-fatigue agent of the
present
invention may be administered by intravenous injection at a frequency of about
three times a
week, preferably about once in two days, to give a daily dose of about 0.1-20
mg, preferably
about 0.5-10 mg.
[0028] If the anti-fatigue agent of the present invention is to be used as
food, the content of
the active ingredient is not limited in any particular way as long as it is
capable of providing
CA 02680751 2009-09-14
- 11 -
the anti-fatigue action of sesamin and it may be chosen as appropriate for the
physical form
of the food (e.g., capsule, tablet, or drink). Depending on the type of the
dioxabicyclo[3.3.0]octane derivative used, the content of the active
ingredient is typically in
the range of 0.001-5 wt%, preferably 0.01-5 wt%, more preferably 0.05-5 wt%.
In the case
of a drink, the content of the active ingredient is preferably in the range of
0.0005-0.05 wt%,
more preferably 0.002-0.01 wt%.
[0029] Insofar as the effect of the dioxabicyclo[3.3.0]octane derivative is
not impaired,
namely, to the extent that incorporation in the dioxabicyclo[3.3.0]octane
derivative will not
produce any unwanted interaction, the anti-fatigue agent of the present
invention may have
mixed therewith other additives such as other physiologically active
ingredients, minerals,
vitamins, hormones, nutritional ingredients, and flavors. All these additives
may be chosen
from among those which are commonly used in pharmaceuticals and foodstuffs.
[0030] The anti-fatigue agent of the present invention is effective not only
in humans but
also in draft animals, hunting dogs, racehorses, pet animals, and various
other kinds of
animals.
EXAMPLES
[0031] The present invention is described in greater detail by means of the
following
examples, to which the present invention is by no means limited.
Example 1. Water Immersion Sleep Disturbed Test
A sesamin/episesamin mixture (sesamin:episesamin = 1:1 in weight ratio) was
used
as a test sample.
[0032] Effectiveness against fatigue was evaluated by the following partial
modification of
the method of Tanaka et al. (Neuroscience, Let. 352, 159-162, 2003). The test
animals
Balb/c male mice (8-week old) were divided into five groups, each consisting
of 12 animals
and having the same average body weight. Four of those five groups were water
immersion
groups, which were kept in breeding cages, not on paper chips but in tap water
(23 C)
supplied to a depth of 7 mm, thereby disturbing sleep of the mice. During a
two-day
immersion in water, the mice were forcibly administered with the test sample
sesamin orally
CA 02680751 2009-09-14
- 12 -
for two days on a one-dose-a-day basis at varying doses of 12.5, 50, and 200
mg/5 ml olive
oil/kg body weight (the group kept under water immersion stress and
administered with
sesamin). The control group mice were forcibly administered with olive oil (5
ml/kg) orally
on a one-dose-a-day basis (the control group kept under water immersion
stress). The
remaining group was a normally kept group and the mice in this group were kept
in breeding
cages where conventional paper chips were laid down, and were forcibly
administered with
olive oil orally on a one-dose-a-day basis (the normally kept control group).
After two
days, each mouse was fitted with a weight at the tail which corresponded to 8%
of its body
weight, and was allowed to swim in a water tank of 18 cm that was filled
with water to a
depth of 30 cm; the time it took for each mouse to have its nose sunk in water
for a period of
at least 10 seconds was measured.
[0033] The mice in the groups kept under water immersion stress could swim for
a shorter
period than the mice in the normally kept group and the degree by which the
shortening of
the swimming time could be controlled in the sesamin administered groups was
measured to
evaluate the effectiveness of sesamin against fatigue. The results are shown
in FIG. 1
(wherein the asterisk represents significant differences at a risk factor of
0.05% in a Student's
t-test).
As is clear from the data shown in FIG. 1, the swimming time of the mice in
the
control group kept under water immersion stress was significantly shorter than
that of the
mice in the normally kept group. However, the shortening of the swimming time
was
markedly controlled in the groups kept under water immersion stress after
being administered
with sesamin. When the swimming time of the control group kept under water
immersion
stress was taken as 100%, those of the groups given sesamin were 150%, 300%
and 133% at
respective doses of 12.5, 50 and 200 mg/kg, indicating that the shortening of
the swimming
time could be effectively controlled by administering sesamin. The shortening
of the
swimming time was controlled most effectively when sesamin was administered in
12.5-
50 mg/kg (more preferably when administered in 50 mg/kg). From these data, it
is obvious
that sesamin is capable of achieving recovery from fatigue by significantly
relieving the
CA 02680751 2009-09-14
- 13 -
fatigue that would otherwise be caused by stress under sleep disturbance from
water
immersion (i.e., increasing the resistance to fatigue).
Example 2. Forced Exercise Test
The test sample used in Example 2 was the same sesamin as in Example 1.
[0034] Sprague Dawley male rats (6-week old) were acclimatized in a test
environment for
a week and the animals that had shown normal growth were subjected to the
test. One day
before the start of the test, the rats were divided into five groups each
consisting of eight
animals. On the day of the test, all animals were starved from the morning and
one group of
rats was assigned as a resting group that was not to be subjected to exercise
stress. The
animals in the other four groups were given a 3-hr exercise stress by means of
a treadmill-
type forced walking apparatus (MK-680 manufactured by MUROMACHI KIKAI CO.,
LTD.) After the end of exercise stress application, the test sample sesamin as
dissolved in
olive oil (5 ml/kg) was forcibly administered orally through a feeding tube at
a dose of 20,
60, or 180 mg/kg. The rats in the control group under exercise stress were
forcibly
administered with olive oil orally at a dose of 5 ml/kg. Thereafter, the
animals were
transferred to an automatograph (Supermex manufactured by MUROMACHI KIKAI CO.,
LTD.) and their motor activity in the dark period was measured.
[0035] The sesamin-induced recovery of rats from the fatigue they suffered as
the result of
forced application of exercise stress was evaluated in terms of motor
activity. The results
are shown in FIG. 2. As is clear from the data in FIG. 2, the motor activity
of the rats in the
control group given exercise stress was considerably smaller than that of the
control group
under no stress. This shows that the rat under exercise stress reflects the
state of fatigue.
In the treated groups of those model animals, an increase in the motor
activity was confirmed
when sesamin was administered in 180 mg/kg. Administering sesamin was
evidently
capable of promoting recovery from fatigue caused by exercise.
Example 3. Forced Exercise Test
The test sample used in Example 3 was the same sesamin as in Example 1.
[0036] Sprague Dawley male rats (10-week old) were acclimatized in a test
environment for
CA 02680751 2009-09-14
- 14 -
a week and the animals that had shown normal growth were subjected to the
test. The rats
were divided into three groups each consisting of eight animals. Then, AIN93G
was mixed
with sesamin to give final concentrations of 0, 0.02, and 0.1% (w/w) to
prepare feeds and the
rats were let to ingest the respective feeds ad libitum for a week.
Thereafter, all animals
were given a 3-hr exercise stress by means of a treadmill-type forced walking
apparatus
(MK-680 manufactured by MUROMACHI KIKAI CO., LTD.) After the end of exercise
stress application, the animals were transferred to an automatograph (Supermex
manufactured by MUROMACHI KIKAI CO., LTD.) and their motor activity in the
dark
period was measured.
[00371 The purpose of the experiment conducted in Example 3 was to determine
how much
of the fatigue that might be caused to the rats upon forced application of
exercise stress
would be prevented by preliminary ingestion of sesamin and this was evaluated
by measuring
the motor activity of the rats. The results are shown in FIG. 3. In comparison
with the
exercise fatigue control group which did not ingest sesamin and the physical
activity of
which was taken as the reference, the group ingesting a mixed feed containing
0.02%
sesamin showed almost the same physical activity whereas the group ingesting a
mixed feed
containing 0.1% sesamin showed an enhanced physical activity. Administering
the mixed
feed containing 0.1% sesamin corresponds to administering about 80 mg of
sesamin per
kilogram of body weight. From these data, it was clear that preliminary
continued ingestion
of sesamin was capable of preventing physical fatigue. What is more,
preventing physical
fatigue by ingesting sesamin before taking exercise was found to effective at
a lower dose
than in Example 2. This suggests that the effective dose of sesamin differs
depending upon
whether it is administered preliminarily or administered after one gets tired.
Example 4. Measuring Fatigue-Causing Substances in the Blood
The fatigue from metabolites in the living body was studied with the variation
in
ketone bodies being used as a marker. To check for any effect on the marker,
the procedure
of Example 1 was slightly modified as described below to prepare sleep-
disturbed animals
under stress by water immersion. The test animals Balb/c male mice (8-week
old) were
CA 02680751 2012-10-26
- 15 -
divided into three groups, consisting of 7-10 animals and having the same
average body
weight. Two of those three groups were water immersion groups, which were kept
in
breeding cages, not on paper chips but in tap water (23 C) supplied to a depth
of 5 ram,
thereby causing the mice to be immersed in water. During a three-day immersion
in water,
the mice were forcibly administered with the test sample sesamin orally for
three days on a
one-dose-a-day basis at a dose of 50 mg/kg body weight as dissolved in olive
oil in an
amount of 5 ml/kg body weight (the group kept under water immersion stress and
administered with sesamin). The control group mice were forcibly administered
with olive
oil (5 ml/kg) orally at the same frequency as the treated group (the control
group kept under
water immersion stress). The remaining group was a normally kept group and the
mice in
this group were kept in breeding cages where conventional paper chips were
laid down, and
were forcibly administered with olive oil (5 ml/kg) orally at the same
frequency as the treated
group (the normally kept control group).
[0038] After three days, blood was drawn from each mouse and the ketone bodies
in the
serum were measured by the enzyme method with a biochemical automatic analyzer
(Model
7070 of Hitachi, Ltd.)
[0039] The results of measurement of ketone bodies are shown in FIG. 4,
wherein the single
and double asterisks represent significant differences at risk factors of
0.05% and 0.01%,
respectively, in a Student's (-test. As is clear from the data shown in FIG.
4, the
concentration of ketone bodies in the sera of the mice in the control group
kept under water
immersion stress (Olive oil) increased significantly compared with the mice in
the normally
kept control group (Cont). On the other hand, the mice in the group kept under
water
immersion stress and administered with sesamin (Sesamin) experienced a
significant control
of the increase in the concentration of ketone bodies.
[0040] The foregoing results suggest that sesamin suppresses the production of
ketone
bodies due to keep under water immersion stress, thereby relieving fatigue or
contributing to
recovery from fatigue so as to achieve effective prevention or treatment of
ketosis.
